Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise
Via Stocktwits
Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets
Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million. 
Via Stocktwits
Topics Earnings
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of... 
Via MarketMinute
Topics Artificial Intelligence Economy
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit
Via Stocktwits
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
Via Stocktwits
Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge
Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock. 
Via Investor's Business Daily
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
Here's a look at the Q3 earnings report from Hims & Hers Health. 
Via Benzinga
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
These two leading drugmakers are fighting over a promising GLP-1 candidate. 
Via The Motley Fool
Topics Intellectual Property
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk. 
Via Investor's Business Daily
Topics Economy Lawsuit
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle
Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal. 
Via Benzinga
Topics Lawsuit
P/E Ratio Insights for Novo Nordisk
 
Via Benzinga
2 Beaten-Down Stocks That Could Be About to Rally
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health
Novo Nordisk (NVO) is a top dividend stock with a 3.6% yield, strong growth, and a sustainable payout backed by exceptional profitability and financial health. 
Via Chartmill
Should You Buy Viking Therapeutics Before Nov. 5?
Viking's stock surged in one trading session after a positive clinical trial report last year. 
Via The Motley Fool
Is It Time to Dump Your Shares of Pfizer?
Pfizer stock has dropped 50% over the past three years. 
Via The Motley Fool
Topics Intellectual Property
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company. 
Via Investor's Business Daily
Topics Law Enforcement Lawsuit
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner
It offers compelling weight-loss drugs -- and a compelling stock price, too. 
Via The Motley Fool
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?
It's not the end of the world for the drugmaker. 
Via The Motley Fool
Topics Government Intellectual Property
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
These two have been neglected by Wall Street too much. 
Via The Motley Fool
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
What Is 1 of the Best Pharmaceutical Stocks to Buy Now?
This pharma giant is entering the rapidly expanding market for weight loss drugs. 
Via The Motley Fool
Viking Therapeutics: High Risk, High Reward Play
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.